Elanco Animal Health Incorporated
ELANNYSETrackedMarket Data VerifiedHealth CarePharmaceuticals
- Coverage
- Coverage universe Identity published; no third-party ESG observation yet.
- ESG profile reviewed
- Last editorial update to this profile.
- Quote
- Last verified closeObservation time is shown beside the price.
- Methodology
- How we rateProvider ratings are shown separately, never blended.
Market overview
Up+USD 0.37 (+1.70%) Day change
The market is closed. This is the last verified closing quote, not an intraday price.
- Open
- USD 22.04
- Previous close
- USD 21.77
- Day high
- USD 22.36
- Day low
- USD 21.77
- Volume
- 5,000,712
- Market cap
- USD 11,057,813,504
View Chart Data
| Date and time | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| USD 20.66 | USD 20.90 | USD 20.39 | USD 20.64 | 6,825,100 | |
| USD 20.10 | USD 20.28 | USD 19.45 | USD 19.76 | 4,599,700 | |
| USD 22.23 | USD 22.84 | USD 22.15 | USD 22.50 | 10,704,800 | |
| USD 21.63 | USD 22.22 | USD 21.03 | USD 21.46 | 4,632,200 | |
| USD 21.99 | USD 22.14 | USD 21.60 | USD 21.99 | 5,885,800 | |
| USD 22.14 | USD 22.35 | USD 21.94 | USD 22.30 | 19,442,800 | |
| USD 23.76 | USD 23.81 | USD 22.79 | USD 22.84 | 5,146,300 | |
| USD 24.78 | USD 24.88 | USD 24.40 | USD 24.40 | 5,345,900 | |
| USD 25.00 | USD 25.09 | USD 24.61 | USD 24.83 | 3,182,600 | |
| USD 26.56 | USD 27.72 | USD 26.51 | USD 26.84 | 7,567,100 | |
| USD 23.11 | USD 23.44 | USD 22.52 | USD 22.68 | 3,425,500 | |
| USD 24.65 | USD 24.77 | USD 22.74 | USD 23.13 | 5,442,100 | |
| USD 23.02 | USD 23.97 | USD 22.99 | USD 23.86 | 5,716,500 | |
| USD 22.33 | USD 22.75 | USD 22.10 | USD 22.15 | 4,236,400 | |
| USD 21.45 | USD 22.09 | USD 21.40 | USD 21.80 | 8,468,800 | |
| USD 23.99 | USD 24.41 | USD 23.64 | USD 23.85 | 10,587,400 | |
| USD 24.90 | USD 25.07 | USD 24.14 | USD 24.29 | 4,476,700 | |
| USD 24.36 | USD 25.20 | USD 24.06 | USD 24.09 | 4,704,900 | |
| USD 25.26 | USD 26.37 | USD 25.26 | USD 25.83 | 4,011,400 | |
| USD 26.29 | USD 26.45 | USD 25.40 | USD 25.72 | 5,391,500 | |
| USD 23.44 | USD 23.81 | USD 23.08 | USD 23.61 | 7,147,400 | |
| USD 24.04 | USD 24.40 | USD 23.90 | USD 23.91 | 3,946,800 | |
| USD 23.34 | USD 23.63 | USD 22.73 | USD 22.74 | 4,609,600 | |
| USD 22.04 | USD 22.36 | USD 21.77 | USD 22.14 | 5,000,700 |
Company Profile & Business Model Overview
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Sustainability Strengths & Catalysts (Pros)
- Product portfolio addressing animal health and welfare: Elanco sells medicines and vaccines for livestock and companion animals that can reduce disease burden, improve animal welfare, and support food-animal productivity, addressing livestock health and p
- Research and late-stage pipeline investments: The company reports progressing a late-stage pipeline with potential new product launches in large market spaces, indicating ongoing R&D investment that could deliver veterinary health innovations and reduced
- Public ESG disclosure and engagement with ratings agencies: Elanco is covered by major ESG data providers (e.g., S&P Global, MSCI) and files regular SEC reports, enabling investor access to sustainability disclosures and corporate governance information.
Material Risks & Governance Concerns (Cons)
- Antimicrobial use and resistance risks: As a producer of veterinary antimicrobials and pharmaceuticals, Elanco faces inherent ESG risks related to antimicrobial usage in animals and the potential contribution to antimicrobial resistance, drawing regulator
- Integration and execution risks from acquisitions and pipeline development: Elanco has noted risks tied to integrating acquisitions, realizing synergies and successfully commercializing pipeline products, which can affect financial stability and long-term
Related ESG Peer Equities
Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.
ESG & Sustainability Rating Breakdown
Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.
Audited Methodology
Formal published scorecards from MSCI ESG Research and Sustainalytics are not currently available for this ticker. The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.
Data integrity and methodology
MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.
Financial & Valuation Fundamentals
Core balance sheet and equity valuation metrics sourced from corporate filings.
Audited Financials
Related ESG Financial Tools & Modeling
ESG Investment Growth Calculator
Project compound future portfolio values versus traditional index benchmarks.
Launch Tool →
Portfolio Carbon Footprint Calculator
Translate your investment capital into financed greenhouse gas emissions.
Launch Tool →
Green Mortgage Calculator
Calculate interest rate discounts on energy-efficient certified homes.
Launch Tool →
Featured Sustainable Investment Research & Guides
Top 12 Impact Investing Apps & Platforms (Reviewed)
Comprehensive review of the best ESG micro-investing and direct indexing apps.
Biblically Responsible Investing (BRI): Top Stocks & Funds
Faith-based screening criteria, ESG alignment, and values-based portfolio strategies.
Top Desalination & Clean Water Infrastructure Stocks
Invest in global clean water purification, reverse osmosis, and municipal utilities.
Best Certified B-Corp Banks & Sustainable Banking
How to align your everyday cash reserves with social and climate impact standards.
Frequently Asked Questions
Direct answers on sustainability scores, risk methodologies, and peer rankings.
What is Elanco Animal Health Incorporated (ELAN)'s ESG rating and sustainability score?
Formal published scorecards from MSCI and Sustainalytics are under ongoing review for Elanco Animal Health Incorporated (ELAN). The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.
Is Elanco Animal Health Incorporated considered an ESG leader or laggard in Health Care?
Independent benchmark status for Elanco Animal Health Incorporated is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.
What are the main ESG risks and controversies for Elanco Animal Health Incorporated?
Key material risks for Elanco Animal Health Incorporated include: Antimicrobial use and resistance risks: As a producer of veterinary antimicrobials and pharmaceuticals, Elanco faces inherent ESG risks related to antimicrobial usage in animals and the potential contribution to antimicrobial resistance, drawing regulator; Integration and execution risks from acquisitions and pipeline development: Elanco has noted risks tied to integrating acquisitions, realizing synergies and successfully commercializing pipeline products, which can affect financial stability and long-term. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.
How does The Impact Investor evaluate ESG stock profiles?
The Impact Investor presents audited third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.